Revenue: As of FY2026 Q1, the actual value is USD 12.13 M, beating the estimate of USD 11.97 M.EPS: As of FY2026 Q1, the actual value is USD -0.32, missing the estimate of USD -0.2733.EBIT: As of FY2026 Q1, the actual value is USD -7.447 M.<h4>Segment Revenue</h4><ul><li>Total Revenue: ClearPoint Neuro, Inc. reported total revenue of $12.1 million for the three months ended March 31, 2026, marking a 43% increase compared to $8.5 million for the same period in 2025.<ul><li>Biologics and Drug Delivery Revenue: Increased by 2% to $4.8 million for the three months ended March 31, 2026, from $4.7 million for the same period in 2025, driven by higher product revenue.<ul><li>Disposable products revenue was $1.9 million in Q1 2026, a 6% increase from $1.8 million in Q1 2025.</li><li>Services and license fees revenue was $2.913 million in Q1 2026, a 0% increase from $2.911 million in Q1 2025.</li></ul></li><li>Neurosurgery Navigation and Therapy Revenue: Increased by 80% to $5.9 million for the three months ended March 31, 2026, from $3.3 million for the same period in 2025, primarily due to additional revenues from IRRAflow product sales and the introduction of the 3.0 operating room navigation software.</li><li>Capital Equipment and Software Revenue: Increased by 177% to $1.4 million for the three months ended March 31, 2026, from $0.5 million for the same period in 2025, mainly due to increased placements of ClearPoint navigation capital and software, IRRAflow control units, and Prism laser units.</li></ul></li></ul><h4>Operational Metrics</h4><ul><li>Gross Profit: Was $7.8 million for the three months ended March 31, 2026, a 51% increase from $5.1 million for the same period in 2025.</li><li>Gross Margin: Was 64% for the three months ended March 31, 2026, compared to 60% for the same period in 2025, primarily due to lower excess and obsolete inventory.</li><li>Research and Development Costs: Were $4.5 million for the three months ended March 31, 2026, a 34% increase from $3.4 million for the same period in 2025, mainly due to higher personnel costs and product/software development costs.</li><li>Sales and Marketing Expenses: Increased by 75% to $6.7 million for the three months ended March 31, 2026, from $3.8 million for the same period in 2025, largely due to additional personnel costs, increased travel costs from expanding teams, and additional amortization expense of acquired intangibles.</li><li>General and Administrative Expenses: Were $5.0 million for the three months ended March 31, 2026, a 22% increase from $4.1 million for the same period in 2025, primarily due to higher occupancy and personnel costs.</li><li>Operating Loss: Was - $8.478 million for the three months ended March 31, 2026, compared to - $6.163 million for the same period in 2025.</li><li>Interest Income: Was $0.4 million for the three months ended March 31, 2026, compared to $0.2 million for the same period in 2025, due to higher investment in U.S. government debt securities.</li><li>Interest Expense: Was - $1.4 million for the three months ended March 31, 2026, compared to no interest expense for the same period in 2025, due to the issuance of notes payable.</li><li>Net Loss: Was - $9.552 million for the three months ended March 31, 2026, compared to - $6.026 million for the same period in 2025, representing a 59% increase in net loss.</li></ul><h4>Cash Flow</h4><ul><li>Net Cash Flows Used in Operating Activities: Amounted to - $8.0 million for the three months ended March 31, 2026, an increase of - $1.8 million from the - $6.2 million used in the same period in 2025, primarily due to a higher net loss partially offset by higher non-cash expenses.</li><li>Net Cash Flows Used in Investing Activities: Were - $0.6 million for the three months ended March 31, 2026, compared to - $0.2 million for the same period in 2025, related to equipment acquisitions.</li><li>Net Cash Flows Used in Financing Activities: Were - $1.8 million for the three months ended March 31, 2026, compared to - $1.4 million for the same period in 2025, primarily consisting of payments for taxes related to shares withheld for restricted stock vesting.</li><li>Cash and Cash Equivalents: Totaled $35.6 million at March 31, 2026.</li></ul><h4>Unique Metrics</h4><ul><li>Biologics and Drug Delivery Partners: ClearPoint Neuro, Inc. had more than 60 partners as of March 31, 2026, consistent with the number in the same period in 2025.</li></ul><h4>Future Outlook and Strategy</h4><ul><li>Core Business Focus: ClearPoint Neuro, Inc. anticipates revenue growth in the coming years due to the IRRAS acquisition, which has expanded product offerings and customer reach. The company expects increased research and development costs for developing devices and services for central nervous system therapeutic delivery, expanding products into the OR and therapeutics space, and investing in the IRRAflow product portfolio and clinical evidence. Sales and marketing expenses are also projected to increase due to a larger combined sales organization and higher personnel-related costs following the IRRAS acquisition.</li><li>Liquidity Outlook: Management believes that the existing cash and cash equivalent balances of $35.6 million at March 31, 2026, are sufficient to support operations and meet obligations for at least the next twelve months. The company may seek to raise additional funds through equity or notes payable for working capital, capital expenditures, or other corporate purposes.</li></ul>

ClearPoint Neuro | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 12.13 M